• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of biomedical materials research. Part B, Applied biomaterials. >Drug loaded nanoparticle coating on totally bioresorbable PLLA stents to prevent in-stent restenosis
【24h】

Drug loaded nanoparticle coating on totally bioresorbable PLLA stents to prevent in-stent restenosis

机译：药物负载纳米粒子涂层在完全生物可吸收的PLLA支架上，以防止支架再狭窄

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Biodegradable polymer poly (dl-lactide) (PDLLA) has been used as drug coating material for drug-eluting stents due to its excellent biocompatibility and sustained drug release ability. However, the uniform thin layer drug eluting coating on a stent not only inhibits the blood vessel's smooth muscle cell overgrowth but also delay the endotheliation process which is often associated with the occurrence of acute thrombosis. Therefore, in this study, we developed a novel coating method using PDLLA nanoparticles (NPs) as a coating to overcome this issue. The average 300 nm sized sirolimus-loaded PDLLA nanoparticles were prepared by a conventional emulsion solvent evaporation method. A low temperature plasma polymerization technology to graft hydrophilic polymers on to poly (l-lactide) stent was used to increase the surface coating efficiency of nanoparticles on the stent. Results showed that sirolimus-loaded nanoparticles can be successfully coated on to the stents with sustained drug release properties. In vitro cell culture study showed the drug loaded nanoparticle coating effectively inhibited the proliferation of smooth muscle cells while still allowed a faster proliferation of endothelial cells, suggesting that the new NP coated bioresorbable stents have the potential to reduce both the occurrence of in-stent restenosis and acute thrombosis. (c) 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 88-95, 2018.
机译：由于其优异的生物相容性和持续的药物释放能力，可生物降解的聚合物聚（DL-丙交酯）（PDLLA）已被用作药物涂料的药物涂料。然而，均匀的薄层药物洗脱涂层在支架上不仅抑制血管的平滑肌细胞过度生长，而且延迟了通常与急性血栓形成的发生相关的内皮过程。因此，在本研究中，我们开发了一种使用PDLLA纳米颗粒（NPS）作为涂层的新型涂布方法以克服该问题。通过常规的乳液溶剂蒸发方法制备平均300nm大小的Siroverimus的PDLLA纳米颗粒。将热血浆聚合技术移植到聚（L-丙交酯）支架上移植到聚（L-丙交酯）支架上，以提高支架上纳米颗粒的表面涂层效率。结果表明，载体负载纳米颗粒可以成功地涂覆到具有持续抑制药物释放性能的支架上。体外细胞培养学研究表明，药物负载纳米粒子涂层有效抑制平滑肌细胞的增殖，同时仍然允许更快的内皮细胞增殖，表明新的NP涂层可吸收支架有可能减少支架内再狭窄的发生和急性血栓形成。 （c）2016 Wiley期刊，Inc.J生物保解率A型B：苹果生物摩特，106B：88-95,2018。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号